Dr. Martine F. Roussel, Department of Tumor Cell Biology, has two exciting new postdoc positions available in her laboratory.
Project 1. MYCN is overexpressed in a variety of childhood cancers, and aberrant MYCN expression is universally associated with a highly aggressive clinical phenotype, metastatic dissemination and low survival rates. The selected postdoc will play a major role in an integrated and multidisciplinary effort to discover and develop PROTACs that will directly degrade the MYCN protein in pediatric solid tumors.
Project 2. Develop novel targeted protein degradation approaches to selectively degrade key oncogenic transcription factors in high risk childhood leukemia and medulloblastoma, two of the leading causes of childhood cancer death. Phenotypic and targeted screening approaches, along with robust computational and structural biology analyses, will be employed to identify and develop molecular glues that will selectively degrade multiple transcription factors. If successful, new therapeutic options for subtypes of pediatric cancers may be identified, and this could lead to further development of therapies to treat many hitherto undruggable cancers.
Project 3. Understand the role of histone methyltransferases in MYC-driven Group3 medulloblastoma, the most aggressive form of this pediatric cerebellar disease. High throughput screens of epigenetic regulators using CRISPR-Cas9 gene editing and shRNA identified several chromatin regulators including two histone methyltransferases that regulate MYC expression and antagonize each other. Biomedical and molecular analysis will unravel how these proteins drive medulloblastoma development and progression. Inhibitors developed against these epigenetic regulators might be potential therapeutic targets that will be tested in pre-clinical trials using mouse models and patient-derived xenografts.
Project 4. To target the p53 pathway in atypical thyroid/rhabdoid tumors (ATRTs). ATRTs are aggressive pediatric brain tumors that occur in very young children for whom novel therapies are warranted. We propose to conduct pre-clinical trials in patient-derived orthotopic xenograft (PDOX) models of ATRT to study the effect of compounds that target the p53 pathway in combination with radiation.
If interested, please contact Dr. Roussel by email at email@example.com.
Applicants with a background in Cancer Biology, Chemical Biology and/or Pharmaceutical Sciences are encouraged to apply. Expertise in using xenograft models and targeted protein degradation approaches is preferred.